针对BIRC5作为一种治疗方法,以克服ASXL1相关的迪西抗性
Ming Yao1, Xiao Jiang2, Fangnan Xiao1
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China; Tianjin Institutes of Health Science, Tianjin, 301600, China.
Cancer letters
|May 10, 2024
概括
ASXL1突变降低了肌肉细胞癌症中对低甲基化剂的敏感性. 用YM-155与decitabine结合向BIRC5可能会克服这种抗药性,改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 低甲基化剂 (HMA) 是神经髓瘤恶性瘤的标准治疗方法.
- 大约50%的患者表现出对HMAs的耐药性.
- ASXL1突变在髓状瘤中很常见,并与HMA反应差相关.
研究的目的:
- 为了研究ASXL1在细胞对HMA-decitabine反应中的作用.
- 确定治疗策略,以克服在ASXL1-突变骨髓瘤癌症中HMA抵抗.
主要方法:
- 利用了急性髓性白血病 (AML) 细胞系和具有ASXL1缺乏症的小鼠骨髓模型.
- 进行了转录组测序来分析基因表达变化.
- 研究了与decitabine结合使用的BIRC5抑制 (YM-155) 的疗效.
主要成果:
- 由于ASXL1的缺陷,导致对德西他治疗的抗性.
- 转录组分析显示,ASXL1缺陷细胞中的细胞周期,细胞亡和组织素修饰途径发生了变化.
- 鉴定出BIRC5是第西他抗性的关键调解者.
- 在ASXL1缺乏细胞中,YM-155与德西他具有协同效应.
结论:
- 通过特定的分子变化,ASXL1缺乏会导致HMA耐药性.
- 准BIRC5代表了重新敏感化ASXL1-突变的骨髓性恶性瘤对decitabine的潜在策略.
- 结合治疗与德西他和BIRC5抑制剂需要进一步研究,以改善治疗结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


